Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
about
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor AntigensRibosome-inactivating proteins: from plant defense to tumor attackCetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.IgE immunotherapy against cancerGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRMRP3: a molecular target for human glioblastoma multiforme immunotherapy.Immunotherapy as a Potential Treatment for Chordoma: a Review.The quest to overcome resistance to EGFR-targeted therapies in cancer.MRl of prostate cancer antigen expression for diagnosis and immunotherapy.New targeted therapies in pancreatic cancer.High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe.Cancer immunotherapy: Progress and challenges in the clinical setting.Hidden immunotherapy targets challenge dogmaImmunotherapy of cancer in 2012.CSPG4 as a target of antibody-based immunotherapy for malignant mesotheliomaThe combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells.An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.Biological therapy and dentistry: a review paper.Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.Immunocombination therapy for high-risk neuroblastoma.Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.Recent advances in technology supporting biopharmaceutical production from mammalian cells.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.Cancer immunotherapy: Breakthrough or "deja vu, all over again"?Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition.Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells.Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies.Optimal use of EGFR inhibitors: challenges, new drugs and future directions
P2860
Q26774669-C8620AAD-9584-4405-98F1-475FFCC1B484Q26828935-0E0F0E04-33F9-4F7F-9E4D-944615FF0925Q27329648-941DFAF5-8E2C-4D37-9FB2-335BFA37E43EQ28081223-2A7CECA8-2B88-4B8B-95EC-2FFEE724FB3CQ28086993-A805CF20-EFC9-449C-8A7B-EF2D6AC4947AQ30988770-2D962069-C6BB-4314-9074-D19292A4C80FQ33276143-9E4AB288-4143-4FDD-B07F-2B326CEA993EQ33725976-73A9DA3F-FAC3-42EC-B7AA-2DCBACCCF47EQ34325715-4377510F-6F20-43D7-8BFD-9A14EC746C22Q35651453-2A7927C7-1658-4449-AB06-DB9DA9FCF72EQ35827605-321747F9-2977-44F2-9709-02D0E82018FEQ36184314-E42B3D99-3551-4BC3-A093-9A82A39459F0Q36184951-85AF2126-9976-413A-9B93-E6C37A079B79Q36243536-14E47319-05DC-4DBE-AD36-06D559824153Q36295924-ECB22458-5044-4B47-92C1-84989813F1B7Q36621615-F94CE1F3-A805-48B6-B2FC-DB7B8D20BA5CQ37029273-6856F6F5-122C-4BFA-9E99-413123332CF6Q37550670-18E302C1-2628-4290-A387-931473D0F176Q37962075-571A04DD-CA3B-4B91-B099-2E31FE75D0E7Q37970537-0035D783-D3E1-4FFC-8AB0-3C0B692416FAQ37991024-F4807352-6327-4E79-8E72-0655C1555D1DQ38041729-CE3263FD-2A91-4050-8EC5-9EBC5F459FB4Q38050998-A774B748-74DF-4F72-9590-AA2CFBFCB801Q38161367-499B1597-60FE-4C61-BE6E-1A9DACB2B674Q38205856-FE5AAB37-448D-47A5-8614-FC058B8B4F3CQ38550541-551A12D5-088A-48A9-A277-391CF21912A8Q39390619-0AC48595-1AF8-4CE9-AF7C-B2F51030B040Q39501392-7D5BCC37-A08A-4D70-8545-EAC2D2D90B14Q39515657-95DA399E-C5BE-4EF2-8246-58314709049CQ41111707-FF220966-FB94-4E28-AD79-E542DEAE5B61Q42290751-A8FFAD45-7C08-4A95-90A0-7AA14819C132Q47111722-212C37A6-90FE-4DAA-9918-C08A72C8DCE9Q58614590-777EB94E-A691-41E2-9BF1-873C5DD8E09B
P2860
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@ast
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@en
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@nl
type
label
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@ast
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@en
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@nl
prefLabel
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@ast
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@en
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@nl
P2093
P2860
P1476
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
@en
P2093
Michael Campoli
Robert Ferris
Soldano Ferrone
Xinhui Wang
P2860
P356
10.1158/1078-0432.CCR-09-2345
P407
P577
2009-12-22T00:00:00Z